Lv4
652 积分 2022-04-08 加入
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
2天前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
2天前
已完结
KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial
2天前
已完结
Nucleotide Exchange on RAS Proteins Using Hydrolysable and Non-hydrolysable Nucleotides
27天前
已完结
Measurement of KRAS-GTPase Activity
27天前
已完结
APC/C coactivators Cdh1 and Cdc20: Mechanistic insights into cancer progression and therapeutic opportunities
1个月前
已完结
Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
1个月前
已完结
Targeting cancer with small molecule pan-KRAS degraders
1个月前
已完结
From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC
1个月前
已完结
皖公网安备34019202002308
